CD8A and neoplasm: Mechanistically, it was also found that αNKG2A-N215 treatment predominantly induced a greater number of CD8+ T and NK cells in tumor grafts while showing little impact on Tregs in mice bearing B16/F1 tumor grafts (Figures 6(D,E,F,G) and S12(A,B)).